FOR IMMEDIATE RELEASE
CONTACT
Erika Wilhelm, Breast Cancer Prevention Partners, media@bcpp.org, 415.539.5005
Janet Nudelman, Campaign for Safe Cosmetics, janet@bcpp.org, 415.321.2909
SAN FRANCISCO, CA — Breast Cancer Prevention Partner (BCPP) and the Campaign for Safe Cosmetics (CSC) strongly urge congressional leaders to reject the inclusion of the Modernization of Cosmetics Regulations Act of 2022 as a rider in the end-of-year spending bill.
While the proposal contains some good policies that would enhance the Food and Drug Administration’s (FDA) authority and oversight of the cosmetics industry, its weak safety standard and far-reaching preemption clause would severely impact the ability of California and over a dozen other states to legislate on cosmetic safety.
Section 608(c) of the Modernization of Cosmetics Regulation Act of 2022 creates an untested, unproven safety standard that has no legal standing, legislative history, or logical reason to replace the more commonly accepted “reasonable certainty of no harm” standard, which has been the FDA’s own standard for the safety of food additives and colors in cosmetics for more than 50 years.
